LBO — LECONTE MEDICAL CENTER
IRR: 20.2% | MOIC: 2.50x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
20.2%
IRR
2.50x
MOIC
$82.7M
Entry EV
$142.9M
Exit EV
$42.6M
Equity Invested
Sources & Uses
S&UTotal · $82.7M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $32.1M | 38.8% | |
| Sub Debt | $8.0M | 9.7% | |
| Equity | $42.6M | 51.5% | |
| Enterprise Value | $80.3M | 97.1% | |
| Transaction Fees | $2.4M | 2.9% | |
| Total Uses | $82.7M | 100.0% |
Interpretation
INTAt 2.50x MOIC and 20.2% IRR over 5 years, this deal exceeds the typical 20% hurdle — strong candidate.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $13.6M |
| Exit Ev | $142.9M |
| Net Debt At Exit | $36.3M |
| Equity At Exit | $106.6M |
| Equity Invested | $42.6M |
| Total Value Created | $64.0M |
| Value From Growth | $58.6M |
| Value From Multiple | $4.0M |
| Value From Deleveraging | $3.8M |